Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MIT Consortium Shares Secrets to Prevent Viral Contaminations

This article was originally published in The Gold Sheet

Executive Summary

MIT provides way for biopharma to share learnings from adventitious agent contamination incidents anonymously. The goal is to better identify, correct and prevent viral and other contaminations.

You may also be interested in...



Experts Explore Ways to Strengthen Protection from Viral Contamination

Adding viral barriers and testing can prevent shutdowns like Genzyme's - or create ones like Glaxo's. What is the right balance? WCBP symposium explores relative merits of treatment barriers and testing. The testing FDA's vaccines office recommends. The combination approach. FDA's advice for winning approval to add treatment barriers.

Biotechs Urged to Prevent Viral Risks That Cost Genzyme Nearly $300 Million

Biotechs should bite the bullet and invest in media treatment to avoid viral contamination, experts say. They point to last year's temporary shutdown of Genzyme's Allston Landing, Mass., which has cost the company $293 million in added expenses and lost revenues so far, and may have reduced the market for its top product by as much as 20 percent. Genzyme looks to add treatment now, but many others still take their chances. What happened when a mouse virus snuck into Genentech's plant 15 years ago? Genentech added high temperature short time heat sterilization treatment and never caught another virus. How Biomarin expanded on Genentech's approach with added layers of protection, including the use of disposable technology. Tips on how to add heat treatment of media for a commercial product.

US FDA Supply Chain Guidance Includes More Stakeholders, More Risks Than CARES Act

Draft guidance on redundancy risk management plans layers risk-based expectations over new statutory requirements to plan more resilient supply chains for critical drugs.

UsernamePublicRestriction

Register

PS000701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel